BioCentury | Mar 17, 2016
Distillery Techniques

Techniques: Human induced pluripotent stem (iPS) cell-derived models of gliomagenesis for drug screening

...of primary human glioma tumor-initiating cells. In a screen of 101 approved cancer drugs, Arranon nelarabine...
...include using the models to screen compound libraries for novel glioma therapies. Novartis AG markets Arranon...
BioCentury | Apr 28, 2014
Strategy

Bigger is better

...Arzerra ofatumumab for first-line and refractory chronic lymphocytic leukemia (CLL) and the nucleoside inhibitor Arranon nelarabine...
...up 25% from £60 million ($95 million) in 2012. GSK doesn't break out sales of Arranon...
BioCentury | Mar 7, 2013
Targets & Mechanisms

ALL emerges from relapse

...would be beneficial to be able to predict response. For example, Ferrando's team showed that nelarabine...
...including glucocorticoids and methotrexate also are active in NT5C2 -mutated leukemias. GlaxoSmithKline plc markets Arranon nelarabine...
BioCentury | Feb 14, 2011
Regulation

Decelerated approval

...difficulties they have run into trying to complete their confirmatory trials. The drugs included Arranon nelarabine...
...CD117-positive gastrointestinal stromal tumors (GIST). Vectibix was approved in 2006 for EGFR-expressing, metastatic colorectal cancer. Arranon...
BioCentury | Jan 7, 2011
Politics & Policy

ODAC to discuss accelerated approval requirements

...to treat CD20 antigen-expressing relapsed or refractory, low-grade, follicular or transformed non-Hodgkin's lymphoma; GSK's Arranon nelarabine...
BioCentury | Nov 15, 2010
Strategy

Innovators pick China

...agents from Phase I to approval, including Gleevec imatinib from Novartis AG and GSK's Arranon nelarabine...
BioCentury | Jan 5, 2009
Company News

Genmab, GlaxoSmithKline deal

...declined to exercise its option to co-promote Arzerra ofatumumab, Bexar tositumomab and Arranon / Atriance nelarabine...
...Arzerra ( HuMax-CD20 ). GSK markets Bexar to treat CD20-positive follicular non-Hodgkin's lymphoma (NHL) and Arranon...
BioCentury | Sep 24, 2007
Strategy

Asset accumulation

...Asset accumulation Product Target Indication Status Atriance nelarabine (A) DNA synthesis Lymphoblastic leukemias Mkt (Nordic rights...
BioCentury | Sep 24, 2007
Strategy

Genmab's commercial stockpile

...also have an option to carry two GSK products - Bexxar in the U.S. and Atriance...
...by a GSK-backed Genmab field force." Bexxar tositumomab is marketed to treat NHL and Atriance nelarabine...
...who have failed two or more chemotherapy regimens. In the U.S., Atriance is marketed as Arranon...
BioCentury | Jul 16, 2007
Company News

GlaxoSmithKline sales and marketing update

...GSK said it does not expect to generate a profit from sales of Atriance nelarabine in...
...price will be but did say that in the U.S., where the drug is called Arranon...
...June, the EMEA's CHMP issued a positive opinion on an MAA for the arabinoside prodrug. Nelarabine...
Items per page:
1 - 10 of 19